Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says

11:53 AM EDT, 10/27/2026 (MT Newswires) -- Edgewise Therapeutics (EWTX) has attracted considerable investor interest in the upcoming phase 3 design for '7500 in hypertrophic cardiomyopathy, representing an opportunity to highlight the drug's differentiated characteristics if the FDA approves a design that uncouples echo monitoring from titration, RBC Capital Markets said in a Tuesday note. The brokerage believes investors would interpret a design aligned with management's messaging as a tacit acknowledgement by the FDA of '7500's unique profile, including no left ventricular ejection fraction impact, potentially driving share upside of as much as 15%, according to the note. If echocardiograms are ultimately not required to guide dosing in the phase III design, the drug's label could look notably cleaner and more convenient than cardiac myosin inhibitors, the note added. The brokerage said it sees a more than 60% probability of success for the phase 3 trial and a clear path to a label that reflects '7500's best-in-disease profile, with the drug potentially capturing a $3.2 billion market opportunity in future revenue. RBC kept an outperform speculative risk rating on Edgewise Therapeutics with a price target of $59. Price: 39.82, Change: +0.65, Percent Change: +1.66